Incyte Corporation
Incyte Corporation (INCY) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INCY · as of Jun 8, 2026
Key Statistics
Explore Incyte Corporation Data
incy stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 44 · Buy rate: 52.3%
The INCY analyst consensus is Buy, based on ratings from 44 Wall Street analysts over the past 3 months. The average 12-month price target is $108.55, representing +6.03% upside from the current price of $102.38.
Competitors & Peers
incy competitorsINCY
BIIB
DGX
GMAB
ILMN
RPRXStock Performance
Full HistoryAbout Incyte Corporation
Incyte Corporation a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers J…
what is incyte corporation · incy stock overview · incyte corporation company profile · who is incyte corporation ceo · incy NASDAQ · incyte corporation headquarters · incyte corporation business segments
About Stock Overview & Key Data
Incyte Corporation (INCY) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 4, 1993. As of the latest trading session, INCY stock price is $102.38, with a market capitalization of $20.5B. The stock has returned +46.49% over the past 12 months and +3.65% year-to-date.
According to 44 Wall Street analysts, the consensus rating for Incyte Corporation stock is Buy, with an average 12-month price target of $108.55. In fiscal year 2025, Incyte Corporation reported revenue of $5.1B and net income of $1.3B. For detailed data — including Incyte Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Incyte Corporation (INCY) stock price is $102.38. The stock is traded on NASDAQ under the ticker symbol INCY. The 52-week range is $66.74 – $112.29.